Clinical data | |
---|---|
Trade names | Trusopt, others |
AHFS/Drugs.com | Monograph |
MedlinePlus | a602022 |
Routes of administration | eye drops |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~33% |
Elimination half-life | 4 months |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII |
|
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.229.271 |
Chemical and physical data | |
Formula | C10H16N2O4S3 |
Molar mass | 324.43 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Dorzolamide, sold under the brand name Trusopt among others, is a medication used to treat high pressure inside the eye, including in cases of glaucoma.[3] It is used as an eye drop.[3] Effects begin within three hours and last for at least eight hours.[3] It is also available as the combination dorzolamide/timolol.[3][4]
Common side effects include eye discomfort, eye redness, taste changes, and blurry vision.[3] Serious side effects include Steven Johnson syndrome.[3] Those allergic to sulfonamides may be allergic to dorzolamide.[3][5] Use is not recommended in pregnancy or breastfeeding.[5] It is a carbonic anhydrase inhibitor and works by decreasing the production of aqueous humor.[3]
Dorzolamide was approved for medical use in the United States in 1994.[3] It is available as a generic medication.[5] In 2022, it was the 201st most commonly prescribed medication in the United States, with more than 2 million prescriptions.[6][7]